Deramiocel FDA Decision: Capricor Trims Staff as Nov 22 DMD Verdict Nears
Capricor cut about 10% of staff and is preparing a solo launch ahead of the November 22 FDA decision on deramiocel for Duchenne muscular dystrophy.
Deramiocel FDA Decision: Capricor Trims Staff as Nov 22 DMD Verdict Nears
Capricor cut about 10% of staff and is preparing a solo launch ahead of the November 22 FDA decision on deramiocel for Duchenne muscular dystrophy.
Etavopivat Filed With FDA and EMA: Novo Nordisk Takes Sickle Cell Pill to Regulators
Novo Nordisk has filed once-daily etavopivat for sickle cell disease with the FDA and EMA after HIBISCUS cut crises by 27%. How it compares with mitapivat.
BioNTech Priority Review Voucher: Why It Is Paying Scholar Rock $205M
BioNTech will pay Scholar Rock $205 million for an FDA priority review voucher, one of the highest prices yet. Here is what it buys and where it may be used.
Novo Nordisk World Diabetes Foundation Pledge: Inside the $200M, 10-Year Commitment
Novo Nordisk commits US$200M over 2027-2036 to the World Diabetes Foundation for care in low- and middle-income countries. The numbers, track record and strategy.
Premarin Discontinued in Canada: Pfizer Pulls Menopause Therapy, Tablets Last to Mid-2027
Pfizer will stop selling Premarin hormone therapy in Canada. The vaginal cream is gone, tablets last to about mid-2027. What changes, why, and what patients can do.
FDA National Priority Voucher Pilot Shelved: What Happens to 22 Drugs
Reuters reports the FDA has shelved its national priority voucher pilot. Here is the scorecard, who is exposed, and what HHS says.
DaVita Fresenius Lawsuit: Washington Says Doctor Noncompetes Lock In Dialysis Monopolies
Washington sued DaVita and Fresenius over noncompetes for dialysis medical directors across 80 centres. What the case alleges and what could change.
Hims & Hers FTC Lawsuit Widens as Five More States Join Health Data Case
Arizona, Florida, Nebraska, Ohio and Wisconsin joined the FTC suit accusing Hims & Hers of sharing health data with Meta and Snap and making plans hard to cancel.
Pfizer Blackstone Deal: $1.5B Bet on a Monthly Obesity Shot, Explained
Blackstone will fund up to $1.5B of Pfizer berobenatide development through 2028, repaid only if the monthly GLP-1 wins US approval. How the deal works.
